

CLAIMS

- An isolated nucleic acid molecule comprising a coding sequence for an immunogenic Streptococcus uberis CAMP factor.
- The nucleic acid molecule of claim 1 2. wherein said coding sequence encodes an amino acid sequence substantially homologous and functionally equivalent to the amino acid sequence shown at positions 10 1 through 256, inclusive, of Figures 4A-4C (SEQ ID -NO: __), or an immunogenic fragment thereof.
- The nucleic acid molecule of claim 1 wherein said coding sequence encodes an amino acid 15 sequence substantially homologous and functionally equivalent to the amino acid sequence shown at positions 29 through 256, inclusive, of Figures 4A-4C (SEQ ID NO:___), or an immunogenic fragment thereof.

20

5

- 4. A recombinant vector comprising:
- (a) a nucleic acid molecule according to claim 1; and
- (b) control elements that are operably linked to said nucleic acid molecule whereby said coding 25 sequence can be transcribed and translated in a host cell, and at least one of said control elements is heterologous to said coding sequence.
- 5. A recombinant vector comprising: 30
 - (a) a nucleic acid molecule according to claim 2; and

I will all the war with the property of the contract of 35

sequence can be transcribed and translated in a host

10


15

cell, and at least one of said control elements is heterologous to said coding sequence.

- 6. A recombinant vector comprising:
- (a) a nucleic acid molecule according to claim3; and
- (b) control elements that are operably linked to said nucleic acid molecule whereby said coding sequence can be transcribed and translated in a host cell, and at least one of said control elements is heterologous to said coding sequence.
- 7. A host cell transformed with the recombinant vector of claim 4.
- 8. A host cell transformed with the recombinant vector of claim 5.
- 9. A host cell transformed with the 20 recombinant vector of claim 6.
 - 10. A method of producing a recombinant CAMP factor comprising:
- (a) providing a population of host cells 25 according to claim 7; and
 - (b) culturing said population of cells under conditions whereby the CAMP factor encoded by the coding sequence present in said recombinant vector is expressed.
- 30 11. A method of producing a recombinant CAMP factor comprising:
 - (a) providing a population of host cells

9000-0030


5



- 12. A method of producing a recombinant CAMP factor comprising:
- (a) providing a population of host cells according to claim 9; and
- (b) culturing said population of cells under 10 conditions whereby the CAMP factor encoded by the coding sequence present in said recombinant vector is expressed.
- 13. A vaccine composition comprising a pharmaceutically acceptable vehicle and at least one immunogenic CAMP factor.
 - 14. The vaccine composition of claim 13, wherein said CAMP factor is a Streptococcus CAMP factor.
- 20 15. The vaccine composition of claim 14, wherein said CAMP factor is a Streptococcus uberis CAMP factor.
- wherein said CAMP factor comprises an amino acid sequence substantially homologous and functionally equivalent to the amino acid sequence shown at positions 1 through 256, inclusive, of Figures 4A-4C (SEQ ID NO:___), or an immunogenic fragment thereof.
 - 17. The vaccine composition of claim 15, wherein said CAMP factor comprises an amino acid sequence

All divilles in a subsequence of a

30



256, inclusive, of Figures 4A-4C (SEQ ID NO:___), or an immunogenic fragment thereof.


- 18. The vaccine composition of claim 13,5 further comprising an adjuvant.
 - 19. The vaccine composition of claim 14, further comprising an adjuvant.
- 10 20. The vaccine composition of claim 15, further comprising an adjuvant.
 - 21. The vaccine composition of claim 16, further comprising an adjuvant.

15

- 22. The vaccine composition of claim 17, further comprising an adjuvant.
- 23. A method of treating or preventing a
 20 bacterial infection in a vertebrate subject comprising
 administering to said subject a therapeutically effective
 amount of a vaccine composition according to claim 13.
- 24. A method of treating or preventing a

 25 bacterial infection in a vertebrate subject comprising
 administering to said subject a therapeutically effective
 amount of a vaccine composition according to claim 18.
- 25. A method of treating or preventing a

 30 streptococcal infection in a vertebrate subject
 comprising administering to said subject a
 therapeutically effective amount of a vaccine composition



30

- 26. A method of treating or preventing a streptococcal infection in a vertebrate subject comprising administering to said subject a therapeutically effective amount of a vaccine composition according to claim 15.
- 27. A method of treating or preventing a streptococcal infection in a vertebrate subject comprising administering to said subject a therapeutically effective amount of a vaccine composition according to claim 16.
- 28. A method of treating or preventing a streptococcal infection in a vertebrate subject comprising administering to said subject a therapeutically effective amount of a vaccine composition according to claim 17.
- 29. A method of treating or preventing a


 20 streptococcal infection in a vertebrate subject

 comprising administering to said subject a

 therapeutically effective amount of a vaccine composition
 according to claim 19.
- 30. A method of treating or preventing a streptococcal infection in a vertebrate subject comprising administering to said subject a therapeutically effective amount of a vaccine composition according to claim 20.
 - 31. A method of treating or preventing a streptococcal infection in a vertebrate subject

nerapeut.warr, erros un en en

35 according to claim 21.



15

20

25


30

dailling .

- 32. A method of treating or preventing a streptococcal infection in a vertebrate subject comprising administering to said subject a therapeutically effective amount of a vaccine composition according to claim 22.
- 33. A method of treating or preventing mastitis in a mammal comprising administering to said mammal a therapeutically effective amount of a vaccine composition according to claim 15.
 - 34. A method of treating or preventing mastitis in a mammal comprising administering to said mammal a therapeutically effective amount of a vaccine composition according to claim 16.
 - astitis in a mammal comprising administering to said mammal a therapeutically effective amount of a vaccine composition according to claim 17.
 - 36. A method of treating or preventing mastitis in a mammal comprising administering to said mammal a therapeutically effective amount of a vaccine composition according to claim 20.
 - 37. A method of treating or preventing mastitis in a mammal comprising administering to said mammal a therapeutically effective amount of a vaccine composition according to claim 21.
 - 38. A method of treating or preventing

35 composition according to claim 22.

Contract to the second contract of the second



- 39. A method of producing a vaccine composition comprising:
- (a) providing at least one immunogenic CAMP factor; and
- (b) combining said CAMP factor with a pharmaceutically acceptable vehicle.
 - 40. The method of claim 39, wherein said CAMP factor is a Streptococcus CAMP factor.
 - 41. The method of claim 40 wherein said CAMP factor is a Streptococcus uberis CAMP factor.
- 42. The method of claim 41, wherein said CAMP

 factor comprises an amino acid sequence substantially
 homologous and functionally equivalent to the amino acid
 sequence shown at positions 1 through 256, inclusive, of
 Figures 4A-4C (SEQ ID NO:___), or an immunogenic fragment
 thereof.
- 43. The method of claim 41, wherein said CAMP factor comprises an amino acid sequence substantially homologous and functionally equivalent to the amino acid sequence shown at positions 29 through 256, inclusive, of Figures 4A-4C (SEQ ID NO:___), or an immunogenic fragment thereof.

5

10

20

35